Phaseline

Companies › Sichuan Baili Pharmaceutical

Sichuan Baili Pharmaceutical: clinical trials, targets and expected readouts

21 active drug programs in 135 registered trials: 57 Phase 1, 53 Phase 2, 25 Phase 3; Oncology, Gastroenterology, Immunology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BL-B01D1
Anti-TROP2 antibody-drug conjugate
TROP-2, TROP2, TACSTD2Phase 3Nasopharyngeal Carcinoma; Small Cell Lung Cancer; Non-small Cell Lung Cancer; Epithelial Ovarian Cancer …Nov 2026
SI-B001
EGFR/HER3 bispecific antibody
EGFR, HER3Phase 3Non-small Cell Lung Adenocarcinoma; Non-small Cell Lung Cancer; Esophageal Squamous Cell Carcinomas; Head and Neck Squamous Cell Carcinoma …Nov 2026
BL-M07D1
anti-HER2 antibody-drug conjugate
ERBB2Phase 3HER2-low Breast Cancer; Gastric Adenocarcinoma; Non-squamous Non-small Cell Lung Cancer; HER2-positive Breast Cancer …Dec 2026
Tislelizumab
Programmed cell death protein 1 inhibitor
PDCD1Phase 3Extensive-stage Small-cell Lung Cancer; Urothelial Carcinoma; Esophageal Squamous Cell CarcinomaDec 2026
SI-B003
PD-1/CTLA-4 bispecific antibody
PDCD1, CTLA4Phase 2Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma; Small Cell Lung Cancer; Cervical Cancer …Nov 2026
BL-M11D1–Phase 2Acute Myeloid Leukemia; Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)Dec 2026
PD-1 Monoclonal Antibody
PD-1 inhibitor
PDCD1Phase 2HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma; Triple-negative Breast Cancer; Extensive-stage Small-cell Lung Cancer; Esophageal Cancer …Dec 2026
Pertuzumab
Receptor protein-tyrosine kinase erbB-2 inhibitor
ERBB2Phase 2HER2-positive Breast CancerDec 2028
BL-M08D1–Phase 1Solid Tumor; Relapsed or Refractory Lymphoid Malignancies; Melanoma; Gastrointestinal TumorsDec 2026
GNC-035
Tetra-specific antibody
–Phase 1Breast Cancer; Hematologic Malignancies; Relapsed/Refractory Chronic Lymphocytic Leukemia; Non-hodgkin's LymphomaDec 2026
GNC-038
Tetra-specific antibody
–Phase 1Primary Central Nervous System Lymphoma; Non Hodgkin Lymphoma; NK/T Cell Lymphoma; Diffuse Large B-cell Lymphoma …Dec 2026
GNC-039
Tetra-specific antibody
–Phase 1Recurrent GliomaDec 2026
BL-M09D1–Phase 1Gastrointestinal Tumor; Non-small Cell Lung CancerMay 2027
BL-M24D1–Phase 1Head and Neck Squamous Cell Carcinoma; Gastrointestinal Tumors; Multiple Myeloma; Non Small Cell Lung CancerNov 2027
BL-ARC002–Phase 1Solid Tumors; Gastrointestinal TumorsDec 2027
Lutetium [177Lu]-BL-ARC001
Radioligand therapy targeting somatostatin receptor 2 (SSTR2)
–Phase 1Lung Cancer; Gastrointestinal TumorsDec 2027
SI-B036
bispecific antibody
–Phase 1Solid Tumor; Breast Cancer; Head and Neck Tumors; Gastrointestinal TumorDec 2028
BL-B16D1–Phase 1Head and Neck Squamous Cell Carcinomas; Breast Cancer; Solid Tumor–
BL-M02D1–Phase 1Locally Advanced or Metastatic Digestive Tract Tumors; Non-small Cell Lung Cancer; Breast Cancer–
BL-M17D1
HER2-targeting therapy (specific mechanism unclear from registry)
–Phase 1Esophageal Cancer; Breast Cancer–
GNC-077–Phase 1Breast Cancer; Non-small Cell Lung Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05393427BL-B01D1Phase 1Locally Advanced or Metastatic Urinary TumorsOncologyDec 2025
NCT05020769SI-B001Phase 2Non-small Cell Lung CancerOncologyDec 2025
NCT05022654SI-B001Phase 2Esophageal Squamous Cell CarcinomasOncologyDec 2025
NCT05044897SI-B001Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2025
NCT05020457SI-B001Phase 2Non Small Cell Lung CancerOncologyDec 2025
NCT04603287SI-B001Phase 1Locally Advanced or Metastatic Epithelial TumorOncologyDec 2025
NCT04606472SI-B003Phase 1Solid TumorOncologyDec 2025
NCT05485753GNC-038Phase 1Primary Central Nervous System LymphomaOncologyDec 2025
NCT04606433GNC-038Phase 1Non Hodgkin LymphomaOncologyDec 2025
NCT05627856GNC-038Phase 1NK/T Cell LymphomaOncologyDec 2025
NCT05192486GNC-038Phase 1Diffuse Large B-cell LymphomaOncologyDec 2025
NCT05160545GNC-035Phase 1Breast CancerOncologyDec 2025
NCT05104775GNC-035Phase 1Hematologic MalignanciesOncologyDec 2025
NCT05944978GNC-035Phase 1Relapsed/Refractory Chronic Lymphocytic LeukemiaOncologyDec 2025
NCT05385692BL-M02D1Phase 1Locally Advanced or Metastatic Digestive Tract TumorsOncologyDec 2025
NCT05949619BL-M02D1Phase 1Non-small Cell Lung CancerOncologyDec 2025
NCT05339685BL-M02D1Phase 1Breast CancerOncologyDec 2025
NCT05943795SI-B001Phase 3Non-small Cell Lung AdenocarcinomaOncologyJul 2026
NCT06469008BL-B16D1Phase 1Head and Neck Squamous Cell CarcinomasOncologyJul 2026
NCT06493864BL-B16D1Phase 1Breast CancerOncologyJul 2026
NCT06475131BL-B16D1Phase 1Solid TumorOncologyJul 2026
NCT06500052BL-M17D1Phase 1Esophageal CancerOncologyAug 2026
NCT06503783BL-M17D1Phase 1Breast CancerOncologyAug 2026
NCT06598787BL-B01D1Phase 2Recurrent GlioblastomaOncologyOct 2026
NCT06423885PD-1 Monoclonal AntibodyPhase 2HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaOncologyOct 2026
NCT06423885BL-M07D1Phase 2HER2-positive Gastric or Gastroesophageal Junction AdenocarcinomaOncologyOct 2026
NCT06609187GNC-077Phase 1Breast CancerOncologyOct 2026
NCT06612840GNC-077Phase 1Non-small Cell Lung CancerOncologyOct 2026
NCT06118333BL-B01D1Phase 3Nasopharyngeal CarcinomaOncologyNov 2026
NCT06668961SI-B001Phase 2Head and Neck Squamous Cell CarcinomaOncologyNov 2026
NCT06668961SI-B003Phase 2Head and Neck Squamous Cell CarcinomaOncologyNov 2026
NCT06500026BL-B01D1Phase 3Small Cell Lung CancerOncologyDec 2026
NCT06382129BL-B01D1Phase 3Non-small Cell Lung CancerOncologyDec 2026
NCT06471205BL-B01D1Phase 2Triple-negative Breast CancerOncologyDec 2026
NCT05965856BL-B01D1Phase 2Urothelial CarcinomaOncologyDec 2026
NCT05924841BL-B01D1Phase 2Small Cell Lung CancerOncologyDec 2026
NCT05990803BL-B01D1Phase 2Cervical CancerOncologyDec 2026
NCT06437509BL-B01D1Phase 2Extensive-stage Small-cell Lung CancerOncologyDec 2026
NCT05956587BL-B01D1Phase 2Non-small Cell Lung CancerOncologyDec 2026
NCT06405425BL-B01D1Phase 2Urothelial CarcinomaOncologyDec 2026
NCT05785039BL-B01D1Phase 2Urinary System TumorOncologyDec 2026
NCT06008054BL-B01D1Phase 2Esophageal CancerOncologyDec 2026
NCT06006169BL-B01D1Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2026
NCT06042894BL-B01D1Phase 2Breast CancerOncologyDec 2026
NCT05194982BL-B01D1Phase 1Locally Advanced or Metastatic Solid TumorOncologyDec 2026
NCT05803018BL-B01D1Phase 1Gynecological Malignant TumorOncologyDec 2026
NCT05262491BL-B01D1Phase 1Gastrointestinal TumorGastroenterologyDec 2026
NCT05470348BL-B01D1Phase 1Breast CancerOncologyDec 2026
NCT06471205PD-1 Monoclonal AntibodyPhase 2Triple-negative Breast CancerOncologyDec 2026
NCT06437509PD-1 Monoclonal AntibodyPhase 2Extensive-stage Small-cell Lung CancerOncologyDec 2026
NCT06008054PD-1 Monoclonal AntibodyPhase 2Esophageal CancerOncologyDec 2026
NCT05054439SI-B001Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2026
NCT05668858SI-B001Phase 1Squamous Cell Carcinoma of Head and NeckOncologyDec 2026
NCT05949606SI-B001Phase 1Non-small Cell Lung CancerOncologyDec 2026
NCT05965856SI-B003Phase 2Urothelial CarcinomaOncologyDec 2026
NCT05924841SI-B003Phase 2Small Cell Lung CancerOncologyDec 2026
NCT05990803SI-B003Phase 2Cervical CancerOncologyDec 2026
NCT05956587SI-B003Phase 2Non-small Cell Lung CancerOncologyDec 2026
NCT06008054SI-B003Phase 2Esophageal CancerOncologyDec 2026
NCT06006169SI-B003Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2026

The 60 nearest readouts of 135 trials; the rest in the app.

Targets

PDCD1 (3) ERBB2 (2) TROP-2 (1) TROP2 (1) TACSTD2 (1) EGFR (1) HER3 (1) CTLA4 (1)

Companies with the same targets

AstraZeneca Beijing Biotech Shanghai Henlius Biotech Akeso Shenyang Sunshine Pharmaceutical Roche Jiangsu HengRui Medicine Chia Tai Tianqing Pharmaceutical Group Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Merck & Co. (MSD)

Companies built like this

Shanghai Henlius Biotech Sichuan Kelun-Biotech Biopharmaceutical Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shenyang Sunshine Pharmaceutical Akeso

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.